Wednesday, February 1, 2023 | Back issues
Courthouse News Service Courthouse News Service

Big Pharma

MANHATTAN - A class of health insurance plans claiming that Sanofi-Aventis underplayed safety risks associated with the antibiotic Ketek cannot proceed as a class, the Second Circuit affirmed Friday.

Read the Top 8

Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.

Loading
Loading...